Annexon Unveils Key Pipeline Milestones, EU Filing, and Strong Cash Runway with Q4 Results
Summary
Annexon reported its fourth quarter and full-year 2025 financial results, alongside significant updates on its clinical pipeline and financial outlook. While the earnings per share beat was previously reported, this release provides substantial new information, including the anticipation of pivotal Phase 3 data for vonaprument in Geographic Atrophy (GA) in Q4 2026. The company also announced the filing of a Marketing Authorization Application (MAA) in Europe for tanruprubart in Guillain-Barré Syndrome (GBS), with a U.S. Biologics License Application (BLA) submission planned for 2026, and expects Proof-of-Concept (POC) data for ANX1502 in autoimmune disease in 2026. These are critical catalysts for a biopharmaceutical company. Furthermore, Annexon reported a strong balance sheet with approximately $238.3 million in cash, cash equivalents, and short-term investments, providing an anticipated cash runway into the second half of 2027, which significantly de-risks its operations. Traders will closely watch the progress of these clinical programs and regulatory submissions, particularly the upcoming Phase 3 data and BLA plans.
At the time of this announcement, ANNX was trading at $4.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $717.9M. The 52-week trading range was $1.29 to $7.18. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.